![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A Retrospective Study to Evaluate the Effect of Switching Antiretroviral Therapy to a Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate in HIV Infected Patients With Suppressed Viral Load In a Clinical Setting - The Switch to Complera (TSC) Study
|
|
|
Reported by Jules Levin
IDSA Oct 8-12 2014 Philadelphia
ANA MONCZOR, MD1, XIAOYING YU, MD, MS2, KAREN J. VIGIL, MD3, CLAUDIA KOZINETZ, PHD, MPH2 and ROBERTO ARDUINO, MD3
1FUNCEI - Fundación Centro de Estudios Infectológicos, Buenos Aires, Argentina, 2Baylor College of Medicine and Study Design and Analysis Core, Baylor-UTHouston Center for AIDS Research, Houston, TX, 3UTHealth, Houston, TX.
IDSA: Switch to Complera in Clinical Practice Usually Safe and Effective - Mark Mascolini - (10/24/14)
![ID1.gif](../images/110314/110314-1/ID1.gif)
![ID2.gif](../images/110314/110314-1/ID2.gif)
![ID3.gif](../images/110314/110314-1/ID3.gif)
![ID4.gif](../images/110314/110314-1/ID4.gif)
![ID5.gif](../images/110314/110314-1/ID5.gif)
![ID6.gif](../images/110314/110314-1/ID6.gif)
![ID7.gif](../images/110314/110314-1/ID7.gif)
![ID8.gif](../images/110314/110314-1/ID8.gif)
![ID9.gif](../images/110314/110314-1/ID9.gif)
![ID10.gif](../images/110314/110314-1/ID10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|